...to treat patients with ER-positive, HER2-negative late-stage breast cancer. The company’s preclinical data included demonstration that the MetAP2...
...hyperglycemia caused by a PI3K/Akt inhibition in healthy mice.TARGETSAKT (AKT1; PKB; PKBA) – Protein kinase B MetAP2 – Methionine aminopeptidase 2 PARP...
...Therapeutics Inc. SynDevRx Inc. Ubiquitin specific peptidase 1 (USP1) Poly(ADP-ribose) polymerase (PARP) Protein kinase B (AKT) (AKT1) (PKB) (PKBA) Methionine aminopeptidase 2 (MetAP2) Phosphoinositide...

...Efung Capital, Lapam Capital and Kaitai Capital. The company’s lead candidate APL-1202, a small molecule MetAP2...
...those statements during the COVID-19 crisis. Targets MetAP2 - Methionine aminopeptidase 2 BioCentury Staff APL-1202 Apexigen Inc. Asieris Pharamaceuticals Co. Ltd. Methionine aminopeptidase 2 (MetAP2) Nanjing...

...believes will be insufficient for FDA to lift a clinical hold on its second-generation methionine aminopeptidase 2 (MetAP2...

...hold Zafgen Inc. (NASDAQ:ZFGN) said FDA agreed to an animal safety study design for methionine aminopeptidase 2 (MetAP2...
...expects top-line data from the animal study by year end (see "Setback for Another Zafgen MetAP2...

...findings appear to be specific to the compound. This is at least the third methionine aminopeptidase 2 (MetAP2...
...Type II diabetes. Zafgen said the agency cited a CV safety risk for the second-generation MetAP2...
...report after market close, was off $0.14 to $4.60 on Monday. Brian Moy, Assistant Editor ZGN-1258 Zafgen Inc. Methionine aminopeptidase 2 (MetAP2...

...Zafgen Inc. (NASDAQ:ZFGN), Boston, Mass. Product: ZGN-1061 Business: Endocrine/Metabolic Molecular target: Methionine aminopeptidase 2 (MetAP2) Description: Second-generation MetAP2...
...diabetes Endpoint: Change in HbA1c value Status: Additional Phase II data Milestone: NA Hongjiang Li ZGN-1061 Zafgen Inc. Methionine aminopeptidase 2 (MetAP2...

...II diabetes. Zafgen said the agency cited a CV safety risk for the second-generation methionine aminopeptidase 2 (MetAP2...
...Zafgen has further characterized the molecular and systems biology of MetAP2 and optimized its second-generation MetAP2...
...compounds target MetAP2. Next quarter, Zafgen expects to begin Phase I testing of another second-generation MetAP2...

...II diabetes. Zafgen said the agency cited a CV safety risk for the second-generation methionine aminopeptidase 2 (MetAP2...
...Zafgen has further characterized the molecular and systems biology of MetAP2 and optimized its second-generation MetAP2...
...compounds target MetAP2. Next quarter, Zafgen expects to begin Phase I testing of another second-generation MetAP2...

...The company expects to present additional data early next year. ZGN-1061 is a second-generation methionine aminopeptidase 2 (MetAP2...
...Diego, Calif. Zafgen Inc. (NASDAQ:ZFGN), Boston, Mass. Jaime De Leon tipifarnib (zarnestra, R115777) ZGN-1061 Kura Oncology Inc. Zafgen Inc. Farnesyl transferase Methionine aminopeptidase 2 (MetAP2) v-Ha-ras...